Anlotinib: clinical trials recruiting now

Phase breakdown

Conditions being studied

Recruiting trials involving Anlotinib

• A Phase II Clinical Study Evaluating Entinostat With or Without Anlotinib + Fulvestrant for the Treatment of Hormone Receptor (HR) -Positive, Human Epidermal Growth Factor Receptor-2 (HER-2) -Negative Advanced Breast Cancer That Relapsed or Progressed After Endocrine Therapy
  NCT07330544 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Anlotinib Plus Immune Checkpoint Inhibitors for Lung Cancer
  NCT04322617 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Anlotinib Plus Whole-Brain Radiotherapy for Brain Metastases in SCLC Patients.
  NCT07443397 · Phase: Phase 3 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Anlotinib With Trastuzumab Deruxtecan for Previously Treated HER2-Low Advanced Breast Cancer
  NCT06331169 · Phase: Phase 1 · Ages: 18 Years to 75 Years · Sex: Female · 1 location
• Circulating Tumor DNA Guided Boost Therapy in Early Triple Negative Breast Patients With Residual Disease After Neoadjuvant Therapy
  NCT06992336 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy
  NCT05582499 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: Female · 1 location
• Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC
  NCT06258642 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Pemetrexed and Carboplatin With or Without Anlotinib Hydrochloride for Osimertinib-resistant Non-squamous NSCLC
  NCT04136535 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Radiotherapy Plus Anlotinib in LA-NSCLC Intolerable to cCRT
  NCT07037680 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Efficacy and Safety of Drug Loaded Microsphere Bronchial Artery Chemoembolization (DEB-BACE) Combined With Anlotinib and Adebelimumab in the Third Line Treatment of Advanced NSCLC: a Prospective, Single Arm, Single Center, Exploratory Clinical Study
  NCT06188650 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• To Evaluate the Efficacy and Safety of Anlotinib Hydrochloride Capsule in Postoperative Non-pCR Patients With Non-small Cell Lung Cancer
  NCT06352008 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location

Common questions

How many recruiting trials involve Anlotinib?

11 recruiting trials across 15 conditions.

Is this list of trials complete?

No. For the full record, search ClinicalTrials.gov.